Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Long-Term Debt Repayments (2020 - 2025)

Bioventus (BVS) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments rose 66.67% year-over-year to $25.0 million, compared with a TTM value of $45.0 million through Dec 2025, up 200.0%, and an annual FY2025 reading of $45.0 million, up 200.0% over the prior year.
  • Long-Term Debt Repayments was $25.0 million for Q4 2025 at Bioventus, up from $10.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $25.0 million in Q4 2022 and bottomed at -$7.5 million in Q4 2021.
  • Average Long-Term Debt Repayments over 5 years is $11.8 million, with a median of $10.0 million recorded in 2025.
  • The sharpest move saw Long-Term Debt Repayments plummeted 116.13% in 2021, then skyrocketed 433.33% in 2022.
  • Year by year, Long-Term Debt Repayments stood at $20.0 million in 2021, then increased by 25.0% to $25.0 million in 2022, then crashed by 72.0% to $7.0 million in 2023, then skyrocketed by 114.29% to $15.0 million in 2024, then surged by 66.67% to $25.0 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for BVS at $25.0 million in Q4 2025, $10.0 million in Q3 2025, and $5.0 million in Q2 2025.